Recent News

• 03.31.2026 - Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
• 03.02.2026 - Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
• 02.12.2026 - Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2026 - 144 Report of proposed sale of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities